Cited by 957Cardiovascular Syncope and Autonomic DisordersHeart Rate Variability and Autonomic ControlDiabetes Management and Research

Cardiovascular autonomic neuropathy in diabetes: clinical impact, assessment, diagnosis, and management

Open access
Spallone, Vincenza, Ziegler, Dan, Freeman, Roy, Bernardi, Luciano, Frontoni, Simona, Pop‐Busui, Rodica, Stevens, Martin, Kempler, Peter +5 more·2011·Diabetes/Metabolism Research and Reviews

Abstract

The Cardiovascular Autonomic Neuropathy (CAN) Subcommittee of the Toronto Consensus Panel on Diabetic Neuropathy worked to update CAN guidelines, with regard to epidemiology, clinical impact, diagnosis, usefulness of CAN testing, and management. CAN is the impairment of cardiovascular autonomic control in the setting of diabetes after exclusion of other causes. The prevalence of confirmed CAN is around 20%, and increases up to 65% with age and diabetes duration. Established risk factors for CAN are glycaemic control in type 1 and a combination of hypertension, dyslipidaemia, obesity, and glycaemic control in type 2 diabetes. CAN is a risk marker of mortality and cardiovascular morbidity, and possibly a progression promoter of diabetic nephropathy. Criteria for CAN diagnosis and staging are: (1) one abnormal cardiovagal test result identifies possible or early CAN; (2) at least two abnormal cardiovagal test results are required for definite or confirmed CAN; and (3) the presence of orthostatic hypotension in addition to abnormal heart rate test results identifies severe or advanced CAN. Progressive stages of CAN are associated with increasingly worse prognosis. CAN assessment is relevant in clinical practice for (1) diagnosis of CAN clinical forms, (2) detection and tailored treatment of CAN clinical correlates (e.g. tachycardia, orthostatic hypotension, non‐dipping, QT interval prolongation), (3) risk stratification for diabetic complications and cardiovascular morbidity and mortality, and (4) modulation of targets of diabetes therapy. Evidence on the cost‐effectiveness of CAN testing is lacking. Apart from the preventive role of intensive glycaemic control in type 1 diabetes, recommendations cannot be made for most therapeutic approaches to CAN. Copyright © 2011 John Wiley & Sons, Ltd.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/dmrr.1239

Cites

65 of 65 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Early detection of CAN may enable tailored interventions that prevent progression and reduce risks of CVD, arrhythmias, myocardial dysfunction leading to CHF, CKD, and all-cause mortality.

    “Timely detection of CAN may help implementation of tailored interventions to prevent its progression and mitigate the risk of associated complications, including CVD, cardiac arrhythmias, myocardial dysfunction leading to congestive heart failure (CHF), CKD, and all-cause mortality.547,614,617–625”

    From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [622]

    The sections on CAN testing for risk stratification and clinical diagnosis (page unavailable in our copy) support detecting CAN to guide tailored treatment and identify risks including cardiovascular events, arrhythmia, heart failure, nephropathy progression, and mortality. The glycaemic-control section reports that intensive treatment can reduce CAN development or progression in specific diabetic populations. The paper does not establish that early detection and tailored interventions prevent or reduce all the listed complications; it describes CAN chiefly as a risk marker for them. (LLM, conf=0.85)

    Experimental — accuracy not yet measured
  • Autonomic neuropathy can increase the risk of exercise-induced injury or adverse events through decreased cardiac responsiveness to exercise, postural hypotension, impaired thermoregulation, impaired night vision due to impaired papillary reaction, and greater susceptibility to hypoglycemia.

    “Autonomic neuropathy can increase the risk of exercise-induced injury or adverse events through decreased cardiac responsiveness to exercise, postural hypotension, impaired thermoregulation, impaired night vision due to impaired papillary reaction, and greater susceptibility to hypoglycemia (277).”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

2 of the 67 references couldn’t be matched to a known paper.

Research works printed but not linked: 5

  1. [8]8. Ziegler D, Gries FA, Mühlen H, et al. Prevalence and clinical correlates of car- diovascular autonomic and peripheral diabetic neuropathy in patients attend- ing diabetes centers. Diabetes Metab 1993; 19: 143-151.
  2. [18]18. Vinik AI, Ziegler D. Diabetic cardiovas- cular autonomic neuropathy. Circula- tion 2007; 115: 387-397.
  3. [43]43. Desouza CV, Bolli GB, Fonseca V. Hypo- glycemia, diabetes, and cardiovascu- lar events. Diabetes Care 2010; 33: 1389-1394.
  4. [55]55. NICE-SUGAR Study Investigators, Fin- fer S, Chittock DR, et al. Intensive ver- sus conventional glucose control in crit- ically ill patients. N Engl J Med 2009; 360: 1283-1297.
  5. [62]62. Freeman R. Clinical practice. Neuro- genic orthostatic hypotension. N Engl J Med 2008; 358: 615-624.

Cited by

Sorted by citations

Authors
Spallone, V., Ziegler, D., Freeman, R., Bernardi, L., Frontoni, S., Pop‐Busui, R., Stevens, M., Kempler, P., Hilsted, J., Tesfaye, S., Low, P., Valensi, P., & Neuropathy, O. B. O. T. T. C. P. O. D.
Affiliations
  • University of Rome Tor Vergata (IT)
  • Düsseldorf University Hospital (DE)
  • Beth Israel Deaconess Medical Center (US)
  • University of Pavia (IT)
  • University of Michigan (US)
  • University of Birmingham (GB)
  • Copenhagen University Hospital (DK)
  • Sheffield Teaching Hospitals NHS Foundation Trust (GB)
  • Mayo Clinic (US)
  • Assistance Publique – Hôpitaux de Paris (FR)
Corresponding author
Spallone, Vincenza
Venue
Diabetes/Metabolism Research and Reviews
Publisher
Wiley
Published
2011-10
Volume
27
Issue
7
Pages
639-653
ISSN
  • 1520-7552 (ISSN-L)
  • 1520-7560
OpenAlex
W2086516175
Cited by
957
References
67
Citations by year
2026: 65 · 2025: 67 · 2024: 78 · 2023: 63 · 2022: 71 · 2021: 86 · 2020: 93 · 2019: 62 · 2018: 78 · 2017: 54 · 2016: 61 · 2015: 60 · 2014: 52 · 2013: 34 · 2012: 24
FWCI
37.71
Type
journal article
Language
en
Open access
Locations
  • Diabetes/Metabolism Research and Reviews (publishedVersion)
  • PubMed (publishedVersion)
  • Deep Blue (University of Michigan) (submittedVersion)
  • Cineca Institutional Research Information System (Tor Vergata University) (submittedVersion)
  • University of Birmingham Research Portal (University of Birmingham) (submittedVersion)
Topics
  • Health Sciences › Medicine › Surgery › Cardiovascular Syncope and Autonomic Disorders
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Rate Variability and Autonomic Control
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Keywords
cardiac autonomic neuropathy, diabetes mellitus, orthostatic hypotension, glycemic control, cardiovascular morbidity and mortality, diabetic nephropathy progression, risk stratification, type 1 diabetes, type 2 diabetes
MeSH terms
Autonomic Nervous System, Blood Glucose, Cardiovascular Diseases, Diabetic Neuropathies, Humans, Prognosis, Disease Management

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review